The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV
- 10 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (4) , 871-880
Abstract
Background: Alterations in brain function and structure, such as depression and neurocognitive impairment, continue to occur in people with human immunodeficiency virus (HIV, PWH) taking suppressive antiretroviral therapy (ART). The lifespan of PWH has improved but the healthspan remains worse than people without HIV, in part because of aging-related diseases. As a result, polypharmacy is common and increases the risk of drug-drug interactions and adverse reactions. Methods: This cross-sectional project investigated the relationship between 7 medication-related metrics (including anticholinergic burden), depressive symptoms, and neurocognitive performance in 491 PWH at a single center in the United States. All participants were taking ART and had plasma HIV RNA ≤ 200 copies/mL. Results: Participants had taken ART for a mean of 6.5 years, and most (57.6%) had CD4+ T-cells >500/µL. All 7 medication-related metrics were associated with worse global neurocognitive performance (P value <.0001 to .0087). Multivariable models confirmed that higher anticholinergic burden (P = .040) and use of benzodiazepines (P = .033), antidepressants (P = .0011), and more total medications (P = .059) were associated with more depressive symptoms (model P < .0001). Use of benzodiazepines (P = .0024) and opiates (P = .043) along with higher anticholinergic burden (P = .066) were also associated with worse neurocognitive performance. Benzodiazepine use was associated with worse performance in all domains and opiate use was associated with worse performance in processing speed, motor function, executive function, and working memory. Conclusions: Use of benzodiazepines, opiates, and anticholinergic drugs contribute to cognitive and mood disorders in PWH. When possible, modifying or deprescribing medications may be beneficial.Keywords
Funding Information
- National Institute on Aging (R01 AG063659)
- National Institute of Mental Health (P30 MH62512, U24 MH100928, R01 MH07345, R25 MH081482)
- National Institute on Drug Abuse (P50 DA26306)
This publication has 67 references indexed in Scilit:
- The challenge of HIV treatment in an era of polypharmacyJournal of the International AIDS Society, 2020
- The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinementsWIREs Computational Statistics, 2019
- Prevalence, Comorbidity, and Correlates of Psychiatric and Substance Use Disorders and Associations with HIV Risk Behaviors in a Multisite Cohort of Women Living with HIVAIDS and Behavior, 2018
- Measuring anticholinergic exposure in patients with dementia: A comparative study of nine anticholinergic risk scalesInternational Journal of Geriatric Psychiatry, 2018
- Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patientsJournal of NeuroVirology, 2015
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findingsPsychopharmacology, 2011
- Cognitive performance and cholinergic transmission: influence of muscarinic and nicotinic receptor blockadeEuropean Archives of Psychiatry and Clinical Neuroscience, 2010
- Antidepressant Efficacy of the Antimuscarinic Drug ScopolamineArchives of General Psychiatry, 2006
- Cognitive Performance and Regional Brain Volume in Human Immunodeficiency Virus Type 1 InfectionArchives of Neurology, 1996